Novartis drug strikes back at bone-marrow disease; Valeant chief pledges $30M to Duke U; Philly judge upholds Topamax verdict;

@FiercePharma: Catch this week's issue of FiercePharmaMarketing here. Issue | Follow @FiercePharma

@TracyStaton: Novartis nabs Merck exec Bruno Strigini to head up oncology business. More | Follow @TracyStaton

@EricPFierce: RT from @FiercePharma: Smells like team spirit: AstraZeneca CEO says Pfizer fight has it pumped to perform. Story | Follow @EricPFierce

@CarlyHFierce: Out with the old, in with the new: Merck, GSK, others put established drugs on the block. News | Follow @CarlyHFierce

@JustinHFierce: #NPPCWPX THE WORLD PORK EXPO HAS A MEDIA ROOM. | Follow @JustinHFierce

> The Novartis ($NVS) blood cancer drug Jakavi did a better job of controlling polycythemia vera, an incurable bone marrow cancer, compared with best available therapy, a study found. Release

> Valeant Pharmaceuticals ($VRX) CEO Michael Pearson committed $30 million in donations to the engineering school at Duke University, his alma mater. Report

> A Philadelphia judge upheld an $11 million verdict against Johnson & Johnson's ($JNJ) Janssen unit in a Topamax liability case. Report

> India's Glenmark Pharmaceuticals threw open the doors on its new antibody manufacturing facility in Switzerland. Release

> Biotech companies fear that a Supreme Court decision in a tech-company case could undermine their method patents. Report

> Price caps in the EU are undercutting generics makers and could ultimately cause companies to pull out of certain markets or cut jobs, a trade group says. Report

Medical Device News

@FierceMedDev: Singapore team designs nanotech glaucoma treatment for sustained release. Story from FierceDrugDelivery | Follow @FierceMedDev

@VarunSaxena2: The EU continues to talk medical device reform. What will the finished regulations look like? More from The National Law Review | Follow @VarunSaxena2

@MichaelGFierce: 'Quadrapeutics' method delivers chemo, nanogold, infrared light and radiation to kill cancer. More from FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: Learning a second language could help ward off dementia, say researchers @UniofEdinburgh. More | Follow @EmilyWFierce

> GE wins FDA approval for automated breast imaging system . News

> Pixium Vision looks to raise $45M in European IPO. Article

> Former ArthroCare top execs convicted of securities fraud scheme. Article

Biotech News

@FierceBiotech: Trending--Sanofi CEO Viehbacher now calls beloved Boston biotech hub his home. More | Follow @FierceBiotech

@JohnCFierce: No. 1 - $31M; No. 2 - $8M: 2013's 10 best-compensated R&D chiefs in biopharma. Report | Follow @JohnCFierce

@DamianFierce: Science pays: 2013's 10 best-compensated R&D chiefs in biopharma. Feature | Follow @DamianFierce

@EmilyMFierce: Genetically engineered malaria parasite could expedite vaccine development. ICYMI from FierceBiotech Research | Follow @EmilyMFierce

> Biotech boom or no, many startups are staying virtual. Story

> Analyst prods Amgen to join the Big Pharma breakup party. More

> Biotech claims a dubious Alzheimer's 'breakthrough.' Item

> Trevi, Complexa bag $38M in VC cash to hit the gas on R&D. Article

> Shire sweetens its arGEN-X deal with a $20M investment. News

Drug Delivery News

> 'Quadrapeutics' method delivers chemo, nanogold, infrared light and radiation to kill cancer. More

> Singapore team designs nanotech glaucoma treatment for sustained release. Article

> First cheek-bound film for opioid dependence nears PDUFA date. Report

> Investors watch RNA therapy companies for signs of future profits. Item

> FDA approves first nasally delivered gel for 'Low T.' Story

Diagnostics News

> Quest and Memorial Sloan-Kettering team for next-generation gene sequencing. Report

> Five urine biomarkers may offer a new way to spot male infertility. Item

> Provista broadens ASU cancer biomarker licensing deal. More

> NanoString to produce companion test for Celgene's blockbuster cancer drug Revlimid. Article

> Almac at ASCO: Dx spots ovarian cancer patients for whom Roche's Avastin would hurt. Story

Pharma Marketing News

> Pfizer launches next new Lipitor copay program, Medicare and ACA included. Report

> GlaxoSmithKline's Chinese reps demand to be repaid for bribes, FT reports. More

> Novartis, Merck KGaA use digital tracking in MS patients to up their competitive game. Story

> AstraZeneca's Crestor gets a boost from Cigna data-crunching deal. Article

> Pfizer launches next new Lipitor copay program, Medicare and ACA included. More

And Finally... Merck & Co. ($MRK) CEO Kenneth Frazier said the company is proud to be an American, but wants to pay lower taxes just as the companies re-domiciling outside the U.S. do. Report